《中国医药科学》杂志欢迎您的投稿!.   今天是:        
朱水染,何彩红,钟晓霞,朱杏妃,吴清梅.依帕司他联合α-硫辛酸方案用于糖尿病周围神经病变的可行性及预后分析[J].中国医药科学,19,(14):31-34        基金项目:
依帕司他联合α-硫辛酸方案用于糖尿病周围神经病变的可行性及预后分析
Feasibility and prognostic analysis of epalrestat combined with α -lipoic acidin the treatment of diabetic peripheral neuropathy
  
DOI:
中文关键词:  糖尿病周围神经病变;依帕司他;α- 硫辛酸;神经传导速度
英文关键词:Diabetic peripheral neuropathy; Epalrestat; α-lipoic acid; Nerve conduction velocity
作者单位
朱水染,何彩红,钟晓霞,朱杏妃,吴清梅 广东省吴川市人民医院内分泌科,广东吴川 524500 
摘要点击次数: 431
全文下载次数: 913
中文摘要:
      目的 探讨对糖尿病周围神经病变患者实施依帕司他联合 α- 硫辛酸方案的效果,为临床提供指导。 方法 采用计算机随机分组法将 2016 年 1 月~ 2018 年 4 月我院 86 例糖尿病周围神经病变患者分为观察组(43 例,采用依帕司他联合 α- 硫辛酸治疗)、对照组(43 例,采用依帕司他治疗)。比较两组患者的疗效、氧化应激指标、腓总神经传导速度、正中神经传导速度、炎症因子水平及不良反应发生情况。 结果 (1)在总有效率方面,观察组(86.05%)高于对照组(62.79%),P < 0.05;(2)观察组患者治疗后 SOD[(36.15±2.85)U/mL] 高于对照组 [(31.35±2.41)U/mL],且 MDA[(3.23±0.23)nmol/mL] 低于对照组 [(4.78±0.42)nmol/mL],P < 0.05;(3)观察组患者治疗后 IL-6[(10.23±2.23)pg/L]、CRP[(8.15±2.10)mg/L] 低于对照组,P < 0.05;(4)观察组患者治疗后腓总神经、正中神经传导速度均高于对照组,P < 0.05;(5)治疗期间,两组患者均未出现明显不良反应。 结论 对糖尿病周围神经病变患者实施依帕司他联合 α- 硫辛酸方案治疗十分可行,能有效改善周围神经病变情况。
英文摘要:
      Objective To explore the effect of epalrestat combined with α-lipoic acidin the patients with diabetic peripheral neuropathy. Methods From January 2016 to April 2018, 86 patients with diabetic peripheral neuropathy in our hospital were randomly divided into observation group (43 cases, treated with epalrestat and α-lipoic acid) and control group (43 cases, treated with epalrestat).The therapeutic effect, oxidative stress index, common peroneal nerve conduction velocity, median nerve conduction velocity, inflammatory factor level and adverse reaction were compared between the two groups. Results (1) The total effective rate in the observation group (86.05%) was higher thanthe control group (62.79%), P < 0.05. (2) After treatment, SOD [(36.15±2.85) U/mL] in the observation group were significantly higher than the control group [(31.35±2.41) U/mL],MDA[(3.23±0.23) nmol/mL] was lower than the control group [(4.78±0.42) nmol/mL],P < 0.05. (3) After treatment, IL-6 [(10.23±2.23) pg/L] and CRP [(8.15±2.10) mg/L] in the observation group were lower than the control group (P < 0.05). (4) The conduction velocity of common peroneal nerve and median nerve in the observation group were higher than the control group (P < 0.05).(5) During the treatment, there were no obvious adverse reactions in both groups. Conclusion It is feasible to treat diabetic peripheral neuropathy patients with epalrestat combined with α-lipoic acid regimen, which can effectively improve the condition of peripheral neuropathy.
查看全文  查看/发表评论  下载PDF阅读器
关闭
关键词: 中国医药科学 中国医学 中国医学科学 中华医学 医学杂志 临床医学杂志 医学期刊 中国预防医学 中华预防医学 预防医学杂志 中国药学 药学杂志
药理杂志 中国中医 中医杂志 中华中医药 中医药杂志 中国医疗 医疗器械杂志 中国中西医结合 中国医药 医药杂志 医药期刊 医药论文 医学论文 科研论文 职称论文
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=08BA79BB04C4219F44B9E66F71056EDDD6DE4B9552F181398A5A51A3E8A27F71925248AEAD05A453A361C173A2180FCCD64A225CAD7E68D3FCD6ED973FFB8D067882152E4654FD50606E809940F7C8C0D253D696899E18A59D7A5E1081410C33CF73BE7EC48294110F5BED5BA64C4DC968F5332F96FAC86F7C60DE82A056455DAFD550C3C8ED7381&pcid=&cid=&jid=&yid=2A8D03AD8076A2E3&aid=&vid=&iid=F3583C8E78166B9E&sid=4AD960B5AD2D111A&eid=339D79302DF62549&fileno=20190994&flag=1&is_more=0">